Endothelin-aldosterone interaction and proteinuria in low-renin hypertension

Journal of Hypertension

Volumn 22, Issue 3, 2004, Pages 573-582

  Elijovich, Fernando ^a,e   Laffer, Cheryl L ^a   Schiffrin, Ernesto L ^d   Gavras, Haralambos ^b   Amador, Elias ^c  

^a LENOX HILL HOSPITAL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Florida Acute Care   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e Hypertension Center   (United States)

Author keywords

Aldosterone; Endothelin; Human; Kidney; Proteinuria; Renin; Sodium dependent hypertension

Indexed keywords

ALDOSTERONE; ENDOTHELIN; RENIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HYPERTENSION; MALE; MULTIVARIATE ANALYSIS; NEPHROSCLEROSIS; PLASMA RENIN ACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PROTEIN INTERACTION; PROTEIN URINE LEVEL; PROTEINURIA; RADIOIMMUNOASSAY; URINALYSIS;

EID: 1642282772     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200403000-00021     Document Type: Article

References (36)

1. Rostand SG, Brown G, Kirk KA, Rutsky EA, Dustan HP. Renal insufficiency in treated essential hypertension. N Engl J Med 1989; 320: 684-688.
2. Bigazzi R, Bianchi S, Baldari D, Sgherri G, Baldari G, Campese VM. Microalbuminuria in salt-sensitive patients: a marker for renal and cardiovascular risk factors. Hypertension 1994; 23:195-199.
3. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension 1986; 8:II127-II134.
4. Deng LY, Day R, Schiffrin EL. Localization of sites of enhanced expression of endothelin-1 in the kidney of DOCA-salt hypertensive rats. J Am Soc Nephrol 1996; 7:1158-1164.
5. Li JS, Larivière R, Schiffrin EL. Effect of a nonselective endothelin antagonist on vascular remodeling in deoxycorticosterone acetate-salt hypertensive rats: evidence for a role of endothelin in vascular hypertrophy. Hypertension 1994; 24:183-188.
6. Kassab S, Miller MT, Novak J, Reckelhoff J, Clower B, Granger JP. Endothelin-A receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertension 1998; 31:397-402.
7. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98:1063-1068.
8. Li JS, Schürch W, Schiffrin EL. Renal and vascular effects of chronic endothelin receptor antagonism in malignant hypertensive rats. Am J Hypertens 1996; 9:803-811.
9. Rossi GP, Belloni AS, Nussdorfer GG, Pessina AC. Endothelin-1 and the adrenal gland. J Cardiovasc Pharmacol 2000; 35:S17-S20.
10. Park JB, Schiffrin EL. ET(A) receptor antagonist prevents blood pressure elevation and vascular remodeling in aldosterone-infused rats. Hypertension 2001; 37:1444-1449.
11. Pu Q, Fritsch Neves M, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling. Hypertension 2003; 42:49-55.
12. Sutsch G, Bertel O, Rickenbacher P, Clozel M, Yandle TG, Nicholls MG, et al. Regulation of aldosterone secretion in patients with chronic congestive heart failure by endothelins. Am J Cardiol 2000; 85: 973-976.
13. Park JB, Schiffrin EL. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1. Am J Hypertens 2002; 15:164-169.
14. Tostes R, Touyz RM, He G, Chen X, Schiffrin EL. Contribution of endothelin-1 to renal activator protein-1 activation and macrophage infiltration in aldosterone-induced hypertension. Clin Sci 2002; 103 (suppl 48):25S-30S.
15. Quaschning T, Ruschitzka F, Niggli B, Lunt CM, Shaw S, Christ M, et al. Influence of aldosterone vs endothelin receptor antagonism on renovascular function in liquorice-induced hypertension. Nephrol Dialysis Transpl 2001; 16:2146-2151.
16. Lim PO, Jung RT, MacDonald TM. Is aldosterone the missing link in refractory hypertension? Aldosterone-to-renin ratio as a marker of inappropriate aldosterone activity. J Hum Hypertens 2002; 16:153-158.
17. Sealey JE, Gerten-Banes J, Laragh JH. The renin system: variations in man measured by radioimmunoassay or bioassay. Kidney Int 1972; 1:240-253.
18. Antunes JR, Dale SL, Melby JC. Simplified radioimmunoassay for aldosterone using antisera to aldosterone-gamma-lactone. Steroids 1976; 28:621-630.
19. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4:303-308.
20. Dluhy RG, Williams GH. Endocrine hypertension. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR (editors): Williams textbook of endocrinology. 9th ed. Philadelphia: W.B. Saunders Co.; 1998. p. 741.
21. Rossi E, Regolisti G, Perazzoli F, Negro A, Davoli S, Davide N, et al. -344C/T polymorphism of CYP11B2 gene in Italian patients with idiopathic low renin hypertension. Am J Hypertens 2001; 14:934-941.
22. Weinberger MH, Stegner JE, Fineberg NS. A comparison of two tests for the assessment of blood pressure responses to sodium. Am J Hypertens 1993; 6:179-184.
23. Campese VM, Romoff MS, Levitan D, Saglikes Y, Friedler RM, Massry SG. Abnormal relationship between sodium intake and sympathetic nervous system activity in salt-sensitive patients with essential hypertension. Kidney Int 1982; 21:371-378.
24. Young WF. Primary aldosteronism: a common and curable form of hypertension. Cardiology 1999; 7:207-214.
25. Collins RD, Weinberger MH, Dowdy AJ, Nokes GW, Gonzales CM, Leutscher JA. Abnormally sustained aldosterone secretion during salt loading in patients with various forms of benign hypertension: relation to plasma renin. J Clin Invest 1970; 49:1415-1426.
26. Saito Y, Nakao K, Mukoyama M, Imura H. Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990; 322:205.
27. Elijovich F, Laffer CL, Amador E, Gavras H, Bresnahan MR, Schiffrin EL. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation 2001; 103:263-268.
28. Ferri C, Bellini C, Desideri G, Giuliani E, De Siati L, Cicogna S, et al. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension 1998; 32:862-868.
29. Letizia C, Cerci S, De Toma G, D'Ambrosio C, De Ciocchis A, Coassin S, et al. High plasma endothelin-1 levels in hypertensive patients with low-renin essential hypertension. J Hum Hypertens 1997; 11:447-451.
30. Chelliah R, Sagnella GA, Markandu ND, MacGregor GA. Urinary protein and essential hypertension in Black and in White people. Hypertension 2002; 39:1064-1070.
31. Lariviere R, Thibault G, Schiffrin EL. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension 1993; 21:294-300.
32. Moreau P, d'Uscio LV, Shaw S, Takase H, Barton M, Luscher TF. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ET(A)-receptor antagonist. Circulation 1997; 96: 1593-1597.
33. Rocha R, Stier CT, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141:3871-3878.
34. Williams ES, Miller JM. Results from late-breaking clinical trial sessions at the American College of Cardiology 51st Annual Scientific Session. J Am Coll Cardiol 2002; 40:1-18.
35. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338:784-790.
36. Nakov R, Pfarr E, Eberle S, on behalf of the HEAT investigators. Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension. Am J Hypertens 2002; 15:583-589.